Market Overview

Thermo Fisher Scientific Completes Acquistion of One Lambda, Says Deal Won't Affect Q3 EPS, Will Add $0.09-0.11 in FY13

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of One Lambda, Inc., the leader in transplant diagnostics. Based in Canoga Park, Calif., One Lambda has approximately 320 employees and had 2011 revenue of $182 million. The business will become part of Thermo Fisher's Specialty Diagnostics Segment.

“We are pleased to welcome One Lambda to our team and significantly increase our access to the attractive transplant diagnostics market,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “One Lambda's tests for tissue typing and antibody detection complement our existing immunosuppressant assays, allowing us to offer a broad menu of tests across the transplant-testing workflow. We are excited about this combination and the opportunities it presents to ultimately improve the lives of transplant patients.”

Posted-In: Earnings News Guidance

 

Most Popular

Related Articles (TMO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free